Apotex gets FDA warning regarding contamination at Toronto plant

04/15/2010 | New York Times (tiered subscription model), The

The FDA sent a warning letter to generic-drug firm Apotex for failing to inform the agency about contamination involving an antihistamine and a diabetes drug produced at its plant in Toronto. The letter is the second time in less than a year that the FDA warned Apotex regarding manufacturing violations. The company did not respond to a newspaper's requests for comment.

View Full Article in:

New York Times (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
SPECIALIST II SYSTEMS INTEGRATION - 140000033P
Abbott
Dallas, TX
Teaching Associate (Hospitality Management)
University of Illinois at Urbana-Champaign
Urbana, IL
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Director, Global Regulatory Affairs
Rodan and Fields, LLC
San Francisco, CA